NEW YORK, July 15, 2016 /PRNewswire/ --
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Alere Inc. (NYSE: ALR), DexCom Inc. (NASDAQ: DXCM), and VWR Corporation (NASDAQ: VWR). Learn more about these stocks by accessing their free notes at:
On Thursday, shares in Madison, Wisconsin headquartered molecular diagnostics company, Exact Sciences Corp. ended the session 2.21% lower at $12.81 with a total volume of 2.68 million shares traded. The Company's shares have surged 36.42% in the last one month, and 71.72% in the previous three months. The stock is trading 51.94% above its 50-day moving average and 57.95% above its 200-day moving average. Moreover, shares of Exact Sciences have a Relative Strength Index (RSI) of 68.10. Sign up and read the free notes on EXAS at:
Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the U.S. and internationally. The stock finished Thursday's session 0.20% higher at $39.45 with a total volume of 797,234 shares traded. The stock is trading below its 50-day moving average by 4.31%. Alere's stock has an RSI of 40.38. The Company was founded in 1981 and is headquartered in Waltham, Massachusetts. The complimentary notes on ALR can be accessed at:
San Diego, California headquartered medical device company, DexCom Inc.'s stock lost 1.54% to close the day at $78.11 with a total volume of 874,106 shares traded. The Company's shares have gained 6.42% in the last one month and 16.51% in the past three months. The stock is trading 11.33% above its 50-day moving average and 6.65% above its 200-day moving average. Additionally, DexCom's stock has an RSI of 61.54. Register for free on Stock-Callers.com and access the latest notes on DXCM at:
On Thursday, shares in VWR Corp. which provides laboratory products, services, and solutions to the life science, general research, and applied markets worldwide, ended the day 0.24% higher at $29.74 with a total volume of 420,689 shares traded. Shares of the Company traded at a PE ratio of 32.19. The Company's shares have advanced 0.78% in the last one month, 13.21% in the previous three months and 14.38% in the past one year. The stock is trading above its 50-day and 200-day moving averages by 2.93% and 12.01%, respectively. Furthermore, shares of VWR have an RSI of 56.65. Get free access to your notes on VWR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit:
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA